Disease mechanisms associated with mutations of the GNE gene

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 4, 2005, Pages 519-527

  Huizing, Marjan ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE; ENZYME INHIBITOR; EPIMERASE; IMMUNOGLOBULIN; MANNOSAMINE; PROTEIN KINASE; SIALIC ACID; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

ABNORMAL URINE COMPOSITION; BIOCHEMISTRY; CARBOHYDRATE METABOLISM; CHROMOSOME 9P; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; ENZYME SYNTHESIS; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INCLUSION BODY MYOSITIS; MISSENSE MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; REVIEW; SIALIC ACID URINE LEVEL; URINALYSIS;

EID: 33645079148     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.11.003     Document Type: Review

References (43)

1. S. Hinderlich et. al. A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase J. Biol. Chem. 272 1997 24313-24318
2. R. Seppala et. al. Sialic acid metabolism in sialuria fibroblasts J. Biol. Chem. 266 1991 7456-7461
3. I. Eisenberg et. al. The UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy Nat. Genet. 29 2001 83-89
4. A. Varki Sialic acids as ligands in recognition phenomena FASEB J. 11 1997 248-255
5. M. Schwarzkopf et. al. Sialylation is essential for early development in mice Proc. Natl. Acad. Sci. U S A 99 2002 5267-5270
6. R. Seppala et. al. Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene define the disease sialuria and the allosteric site of the enzyme Am. J. Hum. Genet. 64 1999 1563-1669
7. J.G. Leroy et. al. Dominant inheritance of sialuria, an inborn error of feedback inhibition Am. J. Hum. Genet. 68 2001 1419-1427
8. I. Eisenberg et. al. Mutations spectrum of GNE in hereditary inclusion body myopathy sparing the quadriceps Hum. Mutat. 21 2003 99
9. K. Effertz et. al. Selective loss of either the epimerase or kinase activity of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase due to site-directed mutagenesis based on sequence alignments J. Biol. Chem. 274 1999 28771-28778
10. S. Noguchi et. al. Reduction of UDP-N-acetylglucosamine 2-epimerase/ N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles J. Biol. Chem. 279 2004 11402-11407
11. S.E. Sparks et. al. Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy Glycobiology 15 2005 1102-1110
12. M. Huizing et. al. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations Mol. Genet. Metab. 81 2004 196-202
13. Y. Tajima et. al. Distal myopathy with rimmed vacuoles: Impaired O-glycan formation in muscular glycoproteins Am. J. Pathol. 166 2005 1121-1130
14. V. Giordanengo et. al. Epigenetic reprogramming of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) in HIV-1-infected CEM T cells FASEB J. 18 2004 1961-1963
15. S. Krause et. al. Localization of UDP-GlcNAc 2-epimerase/ManAc kinase (GNE) in the Golgi complex and the nucleus of mammalian cells Exp. Cell Res. 304 2005 365-379
16. R. Horstkorte et. al. Protein kinase C phosphorylates and regulates UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase FEBS Lett. 470 2000 315-318
17. S.M. Lawrence et. al. Cloning and expression of the human N-acetylneuraminic acid phosphate synthase gene with 2-keto-3-deoxy- d -glycero- d -galacto-nononic acid biosynthetic ability J. Biol. Chem. 275 2000 17869-17877
18. A.K. Münster et. al. Mammalian cytidine 5′-monophosphate N-acetylneuraminic acid synthetase: A nuclear protein with evolutionarily conserved structural motifs Proc. Natl. Acad. Sci. U S A 95 1998 9140-9145
19. A. Harduin-Lepers et. al. The animal sialyltransferases and sialyltransferase-related genes: A phylogenetic approach Glycobiology 15 2005 805-817
20. I. Martinez-Duncker et. al. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter Blood 105 2005 2671-2676
21. S.J. Luchansky et. al. GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism J. Biol. Chem. 278 2003 8035-8042
22. S. Hinderlich et. al. Purification and characterization of N-acetylglucosamine kinase from rat liver - comparison with UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase Eur. J. Biochem. 252 1998 133-139
23. F.W. Verheijen et. al. A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases Nat. Genet. 23 1999 462-465
24. H. Ferreira et. al. Sialuria in a Portuguese girl: Clinical, biochemical, and molecular characteristics Mol. Genet. Metab. 67 1999 131-137
25. G.M. Enns et. al. Clinical course and biochemistry of sialuria J. Inherit. Metab. Dis. 24 2001 328-336
26. C.A. Stanley et. al. Hyperinsulinism and hyperammonia in infants with regulatory mutations of the glutamate dehydrogenase gene N. Engl. J. Med. 338 1998 1352-1357
27. J. Fang et. al. Expression, purification and characterization of human glutamate dehydrogenase (GDH) allosteric regulatory mutations Biochem. J. 363 Pt 1 2002 81-87
28. V.M. Miller et. al. Allele-specific silencing of dominant disease genes Proc. Natl. Acad. Sci. U S A 100 2003 7195-7200
29. R.C. Griggs et. al. Inclusion body myositis and myopathies Ann. Neurol. 38 1995 705-715
30. K. Sivakumar M.C. Dalakas The spectrum of familial inclusion body myopathies in 13 families and description of a quadriceps sparing phenotype in non-Iranian Jews Neurology 47 1996 977-984
31. I. Yabe et. al. GNE mutations causing distal myopathy with rimmed vacuoles with inflammation Neurology 61 2003 384-386
32. D.E. Michele et. al. Dystrophin-glycoprotein complex: Post-translational processing and dystroglycan function J. Biol. Chem. 278 2003 15457-15460
33. S.J. Winder The complexities of dystroglycan Trends Biochem. Sci. 26 2001 118-124
34. I. Salama et. al. No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation Biochem. Biophys. Res. Commun. 328 2005 221-226
35. E. Gottlieb et. al. Single nucleotide polymorphisms in the dystroglycan gene do not correlate with disease severity in hereditary inclusion body myopathy Mol. Genet. Metab. 86 2005 244-249
36. D. Darvish Magnesium may help patients with recessive hereditary inclusion body myopathy, a pathological review Med. Hypotheses 60 2003 94-101
37. C. Oetke et. al. Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells Eur. J. Biochem. 268 2001 4553-4561
38. H.H. Chou et. al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence Proc. Natl. Acad. Sci. U S A 95 1998 11751-11756
39. N.W. Charter et. al. Biosynthetic incorporation of unnatural sialic acids into polysialic acid on neural cells Glycobiology 10 2000 1049-1056
40. A. Blume et. al. 2′,3′-Dialdehydo-UDP-N-acetylglucosamine inhibits UDP-N-acetylglucosamine 2-epimerase, the key enzyme of sialic acid biosynthesis FEBS Lett. 521 2002 127-132
41. L.R. Mantley et. al. Efficient biochemical engineering of cellular sialic acids using an unphysiological sialic acid precursor in cells lacking UDP-N-acetylglucosamine 2-epimerase FEBS Lett. 503 2001 80-84
42. R.L. Sohn E. Gussoni Stem cell therapy for muscular dystrophy Expert Opin. Biol. Ther. 4 2004 1-9
43. J.A. Wolff V. Budker The mechanism of naked DNA uptake and expression Adv. Genet. 54 2005 3-20